chronic myeloid leukemia (Cancer)
Information
- Disease name
- chronic myeloid leukemia
- Disease ID
- DOID:8552
- Description
- "A myeloid leukemia that is characterized by over production of white blood cells." [url:http\://www.cancer.gov/dictionary?CdrID=46755]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00710892 | Active, not recruiting | Phase 1 | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | December 2008 | July 2026 |
| NCT04233346 | Active, not recruiting | Phase 2 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | July 9, 2020 | December 31, 2025 |
| NCT04645706 | Active, not recruiting | Innate T Cells and TKI Discontinuation | April 20, 2021 | April 2028 | |
| NCT03193281 | Active, not recruiting | Phase 2 | KISS Study: Kinase Inhibition With Sprycel Start up | July 17, 2017 | December 31, 2025 |
| NCT04013685 | Active, not recruiting | Phase 1 | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | November 21, 2019 | July 2026 |
| NCT03906292 | Active, not recruiting | Phase 2 | Frontline Asciminib Combination in Chronic Phase CML | August 19, 2019 | December 2027 |
| NCT03709017 | Active, not recruiting | Iclusig PMS in CML or Ph+ALL Patients | August 7, 2018 | June 2023 | |
| NCT03874858 | Active, not recruiting | Phase 2 | De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination | March 22, 2019 | December 31, 2026 |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT02917720 | Active, not recruiting | Phase 2 | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients | September 2016 | September 2027 |
| NCT01698905 | Active, not recruiting | Phase 2 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) | December 20, 2012 | January 24, 2025 |
| NCT06233890 | Active, not recruiting | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia | May 12, 2023 | May 12, 2026 | |
| NCT04578847 | Active, not recruiting | Phase 2 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | January 15, 2020 | January 15, 2025 |
| NCT00905593 | Approved for marketing | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | September 2008 | ||
| NCT00854841 | Available | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | |||
| NCT00219752 | Completed | Phase 2 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years | May 2002 | May 2007 |
| NCT00257647 | Completed | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) | September 2005 | November 2007 | |
| NCT00261846 | Completed | Phase 2 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | January 18, 2006 | August 6, 2015 |
| NCT00267085 | Completed | Phase 2 | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | December 2005 | July 2008 |
| NCT00303290 | Completed | Phase 1 | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | January 2000 | November 2014 |
| NCT00352677 | Completed | Phase 1 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | July 2006 | May 2008 |
| NCT00354120 | Completed | Phase 2/Phase 3 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | March 2005 | August 2011 |
| NCT00375219 | Completed | Phase 2 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | September 20, 2006 | June 28, 2013 |
| NCT00435864 | Completed | N/A | Natural Killer Index From Hematopoietic Stem Cell Graft | April 2007 | November 2013 |
| NCT00001144 | Completed | Phase 2 | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia | October 1999 | October 2002 |
| NCT00460694 | Completed | Phase 1/Phase 2 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies | August 2006 | December 2012 |
| NCT00462943 | Completed | Phase 2 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | March 7, 2007 | June 27, 2013 |
| NCT00469014 | Completed | Phase 2 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | September 2006 | March 2013 |
| NCT00469729 | Completed | Phase 2/Phase 3 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | October 2007 | June 2015 |
| NCT00481052 | Completed | Phase 2 | Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase | June 23, 2007 | April 30, 2018 |
| NCT00493181 | Completed | Phase 2 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | October 2005 | January 2011 |
| NCT00511303 | Completed | Phase 2 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | August 2000 | |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT00514488 | Completed | Phase 3 | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) | June 2004 | |
| NCT00514969 | Completed | Phase 2 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase | August 2000 | |
| NCT00516152 | Completed | Phase 2 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | November 2002 | November 2007 |
| NCT00574873 | Completed | Phase 3 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | February 5, 2008 | May 27, 2015 |
| NCT00460629 | Completed | Phase 1/Phase 2 | Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | March 2005 | |
| NCT00001432 | Completed | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | March 1995 | November 2003 | |
| NCT00038675 | Completed | N/A | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | June 2001 | November 2013 |
| NCT00061581 | Completed | Phase 2 | Experimental Bone Marrow Transplant Protocol | May 19, 2003 | June 14, 2017 |
| NCT00067028 | Completed | Phase 2 | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | December 2003 | June 2013 |
| NCT00101595 | Completed | Phase 2 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | January 2005 | December 2007 |
| NCT00101660 | Completed | Phase 2 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | February 2005 | April 2008 |
| NCT00101816 | Completed | Phase 2 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | December 2004 | March 2008 |
| NCT00103844 | Completed | Phase 2 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | February 2005 | March 2008 |
| NCT00143559 | Completed | Phase 2 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | August 2005 | January 2009 |
| NCT00145613 | Completed | Phase 2 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | June 2003 | February 2009 |
| NCT00145626 | Completed | Phase 2 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | May 2004 | July 2016 |
| NCT00152139 | Completed | Phase 3 | Stem Cell Transplantation for Patients With Hematologic Malignancies | May 2002 | January 2009 |
| NCT00219726 | Completed | Phase 2 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | May 2002 | July 2007 |
| NCT00219739 | Completed | Phase 3 | STI571 ProspectIve RandomIzed Trial: SPIRIT | September 2003 | December 2014 |
| NCT00632255 | Completed | Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment | January 2008 | May 2009 | |
| NCT00750659 | Completed | Phase 2 | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | July 2009 | April 2016 |
| NCT00786812 | Completed | Phase 4 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | August 2008 | January 2012 |
| NCT00815321 | Completed | Phase 2 | Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy | December 2008 | November 2011 |
| NCT00827138 | Completed | Phase 1 | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | March 2009 | January 2013 |
| NCT00845221 | Completed | Phase 4 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | July 2004 | |
| NCT00852566 | Completed | Phase 2 | Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | March 2009 | December 2015 |
| NCT00858806 | Completed | Phase 2 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy | April 2008 | December 2014 |
| NCT00866736 | Completed | Phase 2 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | March 2009 | June 2012 |
| NCT00896129 | Completed | Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy | March 2010 | December 2010 | |
| NCT00947830 | Completed | Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia | July 2009 | April 2012 | |
| NCT00988013 | Completed | N/A | Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies | September 2009 | February 2016 |
| NCT01068301 | Completed | Phase 1 | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | May 2010 | October 2013 |
| NCT01077544 | Completed | Phase 1 | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | April 14, 2011 | July 1, 2015 |
| NCT01114087 | Completed | N/A | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility | October 2008 | May 2009 |
| NCT01126892 | Completed | Phase 3 | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | January 2009 | April 2011 |
| NCT01167166 | Completed | Phase 1/Phase 2 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | July 2010 | June 2014 |
| NCT01207440 | Completed | Phase 2 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | September 30, 2010 | January 17, 2019 |
| NCT01215487 | Completed | A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib | October 2010 | May 31, 2020 | |
| NCT01220648 | Completed | Phase 1 | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) | April 2012 | January 2014 |
| NCT01223898 | Completed | Phase 1 | To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib | June 2010 | December 2013 |
| NCT01244750 | Completed | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting | December 2, 2010 | January 8, 2020 | |
| NCT01252589 | Completed | Patient Reported Outcomes in Chronic Myeloid Leukemia | November 2010 | September 2013 | |
| NCT01254188 | Completed | Phase 3 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients | April 2011 | November 2014 |
| NCT01270984 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects | November 2010 | December 2010 |
| NCT01275196 | Completed | Phase 3 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | April 2011 | October 2014 |
| NCT01290302 | Completed | Phase 1 | Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia | October 2010 | |
| NCT01297543 | Completed | Phase 1/Phase 2 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | March 2011 | January 2015 |
| NCT01342679 | Completed | Phase 2 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib | April 2011 | September 2014 |
| NCT01344876 | Completed | Phase 1 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | April 2011 | April 2014 |
| NCT01350245 | Completed | Phase 2 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | July 2010 | May 2014 |
| NCT01394666 | Completed | Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) | May 2011 | December 2012 | |
| NCT01490853 | Completed | Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy | October 2009 | December 2014 | |
| NCT01535391 | Completed | Phase 3 | Nilotinib in PH+, BCR-, ABL+ CML Patients | January 2012 | April 27, 2018 |
| NCT01572662 | Completed | Phase 2 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | April 11, 2012 | August 11, 2022 |
| NCT01578213 | Completed | Phase 4 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients | November 9, 2011 | November 28, 2018 |
| NCT01596114 | Completed | Phase 3 | European Stop Tyrosine Kinase Inhibitor Study | May 30, 2012 | December 31, 2019 |
| NCT01606579 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | July 2012 | December 30, 2016 |
| NCT01657604 | Completed | Phase 3 | TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | August 24, 2012 | May 31, 2022 |
| NCT01683123 | Completed | Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT | July 2007 | October 2012 | |
| NCT01751919 | Completed | Phase 1 | A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | May 2012 | August 2012 |
| NCT01795716 | Completed | Phase 1 | Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body | September 2012 | June 2013 |
| NCT01805843 | Completed | Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia | July 2012 | June 2015 | |
| NCT01819558 | Completed | Phase 1/Phase 2 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy | March 2013 | March 2015 |
| NCT01903733 | Completed | N/A | Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 | August 28, 2013 | June 5, 2020 |
| NCT02011945 | Completed | Phase 1 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | February 7, 2014 | December 26, 2018 |
| NCT02016833 | Completed | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | October 2013 | December 2014 | |
| NCT02057185 | Completed | Occupational Status and Hematological Disease | September 8, 2014 | November 11, 2015 | |
| NCT02103322 | Completed | Phase 2/Phase 3 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | February 2014 | June 2014 |
| NCT02129582 | Completed | Phase 1 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | November 5, 2014 | March 5, 2020 |
| NCT02253277 | Completed | Phase 1 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | February 18, 2015 | April 3, 2018 |
| NCT02353728 | Completed | Phase 2 | Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy | January 2015 | February 2021 |
| NCT02487069 | Completed | N/A | Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy | June 2015 | February 29, 2020 |
| NCT02546674 | Completed | Phase 4 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. | February 18, 2016 | March 25, 2021 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT02707393 | Completed | Phase 2/Phase 3 | Allogeneic Stem Cell Transplantation for Children With CML | April 30, 2009 | December 1, 2020 |
| NCT02767388 | Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery | September 1, 2016 | March 15, 2018 | |
| NCT02810990 | Completed | Phase 2 | Bosutinib in Elderly Chronic Myeloid Leukemia | November 17, 2016 | June 22, 2022 |
| NCT02842320 | Completed | N/A | Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) | October 14, 2015 | July 15, 2020 |
| NCT02890758 | Completed | Phase 1 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | May 22, 2018 | February 17, 2023 |
| NCT02895542 | Completed | Preparatory Work to Assess Adherence to Oral Chemotherapy | December 20, 2016 | April 28, 2017 | |
| NCT02896829 | Completed | Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia | April 3, 2013 | April 2019 | |
| NCT03018223 | Completed | Phase 1 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | January 31, 2017 | March 18, 2021 |
| NCT03262974 | Completed | Effect of Pharmacogenetics on Imatinib Plasma Level and Response | October 29, 2017 | October 1, 2023 | |
| NCT03455517 | Completed | Phase 2 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia | October 31, 2018 | May 11, 2023 |
| NCT03509896 | Completed | Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | November 30, 2017 | September 28, 2019 | |
| NCT03540654 | Completed | Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach | December 7, 2016 | April 2019 | |
| NCT03678454 | Completed | Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | February 3, 2017 | March 31, 2022 | |
| NCT03885830 | Completed | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | June 20, 2019 | June 15, 2022 | |
| NCT03996096 | Completed | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. | April 23, 2019 | March 16, 2023 | |
| NCT04048564 | Completed | Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) | February 23, 2018 | July 3, 2023 | |
| NCT04089839 | Completed | A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting | April 21, 2016 | January 16, 2020 | |
| NCT04595955 | Completed | N/A | Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life | July 1, 2019 | August 31, 2020 |
| NCT04605211 | Completed | N/A | A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | September 18, 2020 | September 30, 2022 |
| NCT05260203 | Completed | N/A | MargheRITA (Remote Intelligence for Therapeutic Adherence) | June 4, 2022 | January 16, 2023 |
| NCT05387330 | Completed | Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment | April 1, 2018 | December 28, 2021 | |
| NCT05421091 | Completed | Special Drug Use-results Surveillance of Scemblix Tablets | July 4, 2022 | February 29, 2024 | |
| NCT05433532 | Completed | Phase 2 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | May 1, 2022 | April 13, 2024 |
| NCT05476562 | Completed | Study Conducted Among Patients With CML | March 8, 2021 | October 15, 2021 | |
| NCT05611216 | Completed | Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation | December 1, 2020 | December 23, 2021 | |
| NCT05619978 | Completed | French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients | May 3, 2021 | October 29, 2021 | |
| NCT05734053 | Completed | Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line | June 28, 2016 | September 8, 2022 | |
| NCT06042660 | Completed | Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis | February 2016 | August 2016 | |
| NCT06148493 | Completed | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | September 20, 2022 | December 15, 2022 | |
| NCT01200017 | No longer available | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | |||
| NCT01549548 | No longer available | Compassionate Use Ponatinib | |||
| NCT00302016 | No longer available | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | January 2006 | ||
| NCT02258490 | No longer available | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | |||
| NCT06398457 | Not yet recruiting | Early Phase 1 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | June 2024 | December 2026 |
| NCT06423911 | Not yet recruiting | Phase 3 | A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML | May 2024 | February 2026 |
| NCT06390306 | Not yet recruiting | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | May 1, 2024 | December 1, 2026 | |
| NCT06355583 | Not yet recruiting | Phase 2 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | April 15, 2024 | May 1, 2027 |
| NCT05440747 | Not yet recruiting | Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | July 31, 2022 | October 31, 2031 | |
| NCT06163430 | Not yet recruiting | Phase 1 | CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | December 13, 2023 | May 31, 2026 |
| NCT06409936 | Not yet recruiting | Phase 2 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | September 2024 | September 2031 |
| NCT06453902 | Not yet recruiting | Phase 2 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | June 15, 2024 | December 15, 2027 |
| NCT04626024 | Recruiting | Phase 2 | Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population | December 22, 2020 | November 15, 2025 |
| NCT05282108 | Recruiting | Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia | July 20, 2022 | August 2024 | |
| NCT05304377 | Recruiting | Phase 1 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | May 22, 2022 | December 2026 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT05362773 | Recruiting | Phase 1 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | July 13, 2022 | March 2025 |
| NCT06229860 | Recruiting | Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia | January 25, 2024 | January 2026 | |
| NCT05400122 | Recruiting | Phase 1 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | September 9, 2022 | June 1, 2026 |
| NCT05413915 | Recruiting | Phase 3 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | June 19, 2023 | December 2025 |
| NCT06236724 | Recruiting | Phase 2 | Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | January 31, 2024 | July 1, 2035 |
| NCT05605379 | Recruiting | CML Pediatric ITK Response According to Molecular Identification at Diagnosis | February 27, 2023 | March 2024 | |
| NCT03326310 | Recruiting | Phase 1 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | September 4, 2018 | September 4, 2025 |
| NCT05701215 | Recruiting | Phase 2 | Venetoclax After TKI to Target Persisting Stem Cells in CML | August 31, 2023 | December 1, 2025 |
| NCT03533816 | Recruiting | Phase 1 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | January 31, 2020 | January 2025 |
| NCT05753384 | Recruiting | Phase 3 | Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System | December 1, 2023 | December 1, 2029 |
| NCT05768711 | Recruiting | Phase 2 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | October 4, 2023 | October 2028 |
| NCT03802695 | Recruiting | Phase 1 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | April 8, 2019 | April 2028 |
| NCT03831776 | Recruiting | Phase 2 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis | March 25, 2019 | March 2028 |
| NCT05800210 | Recruiting | Phase 2 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | May 3, 2024 | May 2027 |
| NCT05943522 | Recruiting | Asciminib RMP Study | July 19, 2023 | July 31, 2025 | |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT01281735 | Recruiting | International Chronic Myeloid Leukemia Pediatric Study | January 2011 | December 2028 | |
| NCT04167683 | Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | October 1, 2023 | December 31, 2026 | |
| NCT04260022 | Recruiting | Phase 1 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | January 9, 2020 | January 31, 2024 |
| NCT06092879 | Recruiting | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | March 6, 2024 | December 15, 2026 | |
| NCT04621851 | Recruiting | Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation | September 30, 2020 | September 30, 2023 | |
| NCT04663100 | Recruiting | N/A | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | February 8, 2021 | December 31, 2023 |
| NCT04769947 | Recruiting | Italian Treatment Free Remission Registry | August 9, 2021 | February 8, 2030 | |
| NCT04835584 | Recruiting | Phase 1/Phase 2 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | May 7, 2021 | June 30, 2026 |
| NCT04943757 | Recruiting | Phase 2 | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies | January 21, 2021 | December 31, 2024 |
| NCT01860456 | Recruiting | TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study | May 2013 | December 31, 2024 | |
| NCT05115630 | Recruiting | Phase 1/Phase 2 | Off-the-shelf NK Cells + SCT for Myeloid Malignancies | April 8, 2022 | June 1, 2024 |
| NCT05130138 | Recruiting | N/A | Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia | January 27, 2022 | November 1, 2025 |
| NCT05236764 | Recruiting | N/A | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion | December 6, 2023 | August 1, 2030 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT04151706 | Suspended | Phase 2 | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML | February 27, 2020 | February 2026 |
| NCT04595851 | Terminated | N/A | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications | March 26, 2021 | July 14, 2022 |
| NCT00895297 | Terminated | Phase 2 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia | February 2010 | November 2011 |
| NCT00968864 | Terminated | Phase 2 | T-cell Depleted Alternative Donor Transplantation | August 2009 | November 2016 |
| NCT01866553 | Terminated | Phase 2 | Nilotinib Plus Pegylated Interferon-α2b in CML | April 2013 | May 1, 2016 |
| NCT02174445 | Terminated | Phase 3 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years | March 2014 | October 2019 |
| NCT02448095 | Terminated | Retrospective Evaluation of CML Patients in the National Compassionate Program | December 22, 2015 | July 17, 2018 | |
| NCT00593554 | Terminated | Phase 2 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | August 7, 2007 | July 28, 2017 |
| NCT02204722 | Terminated | Phase 4 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients | October 13, 2014 | January 9, 2018 |
| NCT00573378 | Terminated | Phase 2 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | September 2007 | December 2015 |
| NCT01650805 | Terminated | Phase 3 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | June 2012 | October 2013 |
| NCT02709083 | Terminated | Phase 2 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | October 2016 | July 2018 |
| NCT02078960 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | October 9, 2014 | November 27, 2017 |
| NCT00522990 | Terminated | Phase 1/Phase 2 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | September 2006 | April 2009 |
| NCT01169753 | Terminated | N/A | Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | May 2011 | February 2013 |
| NCT00464113 | Terminated | Phase 1 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | May 2007 | April 2011 |
| NCT01749111 | Terminated | Phase 3 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis | December 2012 | August 2016 |
| NCT00511121 | Terminated | Phase 2 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | April 2001 | |
| NCT00461929 | Terminated | Phase 4 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib | February 2005 | December 2008 |
| NCT03696537 | Terminated | Phase 1 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | August 29, 2018 | April 13, 2021 |
| NCT00790855 | Terminated | Phase 1/Phase 2 | Bendamustine in Acute Leukemia and MDS | November 2008 | March 2012 |
| NCT00531310 | Terminated | Phase 2 | Reduced Intensity AlloSCT in(CML) With Persistent Disease | January 2003 | June 2010 |
| NCT00219765 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | May 2001 | January 2006 |
| NCT01073436 | Terminated | Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha | May 2009 | November 2011 | |
| NCT01490983 | Terminated | N/A | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | April 2009 | December 2014 |
| NCT02869256 | Unknown status | Regional Central Database Recording of Chronic Myeloid Leukemia | January 2014 | January 2024 | |
| NCT03062436 | Unknown status | N/A | To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission | August 1, 2017 | December 2020 |
| NCT03075969 | Unknown status | Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia | August 3, 2017 | December 2019 | |
| NCT03228303 | Unknown status | Early Phase 1 | Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | December 1, 2017 | August 1, 2020 |
| NCT03241199 | Unknown status | Phase 2 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | August 1, 2017 | January 1, 2021 |
| NCT00146913 | Unknown status | Phase 2 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | March 2004 | |
| NCT00598624 | Unknown status | Phase 2 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) | September 2005 | December 2010 |
| NCT03625583 | Unknown status | The Hong Kong CML Registry | April 1, 2018 | September 30, 2023 | |
| NCT01761890 | Unknown status | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib | January 28, 2014 | December 2022 | |
| NCT00965224 | Unknown status | Phase 2 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | January 2010 | |
| NCT03795779 | Unknown status | Early Phase 1 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | March 1, 2018 | September 30, 2022 |
| NCT04818619 | Unknown status | TIGIT in Patients With Chronic Myeloid Leukemia | April 2021 | December 2022 | |
| NCT01802450 | Unknown status | Phase 2 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase | March 2013 | December 2016 |
| NCT00328237 | Unknown status | Phase 2 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | November 2005 | |
| NCT02268370 | Unknown status | Phase 2 | Treatment-free Remission Accomplished With Dasatinib in Patients With CML | October 2014 | October 2021 |
| NCT00327262 | Unknown status | Phase 3 | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase | January 2004 | December 2008 |
| NCT02164903 | Unknown status | LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients | September 11, 2014 | October 2018 | |
| NCT04043676 | Unknown status | Phase 2 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | April 30, 2019 | April 30, 2023 |
| NCT04104035 | Unknown status | Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response | August 13, 2019 | January 2021 | |
| NCT04991532 | Unknown status | Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells | June 20, 2021 | December 2022 | |
| NCT04155411 | Unknown status | Phase 4 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | December 1, 2019 | December 1, 2023 |
| NCT04156256 | Unknown status | Early Phase 1 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | March 1, 2018 | September 30, 2020 |
| NCT02007811 | Unknown status | Phase 1/Phase 2 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | November 2013 | December 2015 |
| NCT02422719 | Unknown status | Phase 2 | Radotinib as 3rd or Later Line Therapy in CP-CML | April 2015 | March 2019 |
| NCT02172365 | Unknown status | Allogeneic SCT for CML, TKI Failure After TKI Failure | March 1, 2014 | December 30, 2020 | |
| NCT01400074 | Unknown status | Phase 3 | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib | January 2009 | June 2014 |
| NCT02398825 | Unknown status | Phase 2 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | June 23, 2016 | February 2023 |
| NCT01562847 | Unknown status | Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib | July 2011 | June 2015 | |
| NCT01564836 | Unknown status | N/A | Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | June 2010 | |
| NCT02317159 | Unknown status | Phase 4 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | February 2015 | July 2017 |
| NCT01627132 | Unknown status | Phase 2 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | February 2012 | January 2019 |
| NCT02885766 | Unknown status | Phase 1/Phase 2 | Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene | July 2016 | May 2020 |
| NCT02883036 | Unknown status | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia | September 2016 | ||
| NCT03348033 | Unknown status | Phase 1/Phase 2 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | March 2019 | March 2023 |
| NCT03353558 | Unknown status | Sleep Assessment in CML | December 2017 | December 2018 | |
| NCT02201459 | Unknown status | Phase 3 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients | August 2014 | August 2019 |
| NCT01752062 | Unknown status | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors | May 2, 2013 | December 2022 | |
| NCT04464889 | Withdrawn | Phase 1 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | July 2, 2020 | July 2025 |
| NCT02663648 | Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | June 2016 | June 2020 | |
| NCT01188889 | Withdrawn | Phase 1/Phase 2 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | September 2013 | December 2017 |
| NCT02115672 | Withdrawn | Phase 1/Phase 2 | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia | November 2014 | November 2018 |
| NCT00162513 | Withdrawn | Phase 1/Phase 2 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | December 2006 | |
| NCT05201183 | Withdrawn | Phase 1/Phase 2 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | October 2023 | April 2029 |
| NCT00570999 | Withdrawn | Phase 2 | Palifermin After Haploidentical PBSCT | February 2008 | January 2013 |
| NCT00349518 | Withdrawn | Phase 2/Phase 3 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | December 2006 |
- Disase is a (Disease Ontology)
- DOID:8692
- Cross Reference ID (Disease Ontology)
- EFO:0000339
- Cross Reference ID (Disease Ontology)
- GARD:6105
- Cross Reference ID (Disease Ontology)
- ICD9CM:205.1
- Cross Reference ID (Disease Ontology)
- ICDO:9863/3
- Cross Reference ID (Disease Ontology)
- KEGG:05220
- Cross Reference ID (Disease Ontology)
- MIM:608232
- Cross Reference ID (Disease Ontology)
- ORDO:521
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154592009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023473
- Exact Synonym (Disease Ontology)
- chronic granulocytic leukaemia
- Exact Synonym (Disease Ontology)
- chronic granulocytic leukemia
- Exact Synonym (Disease Ontology)
- chronic myelogenous leukaemia
- Exact Synonym (Disease Ontology)
- chronic myelogenous leukemia
- Exact Synonym (Disease Ontology)
- chronic myeloid leukaemia
- Exact Synonym (Disease Ontology)
- CML
- Exact Synonym (Disease Ontology)
- CML - chronic Myelogenous Leukemia
- Exact Synonym (Disease Ontology)
- Myeloid Leukemia, chronic
- OrphaNumber from OrphaNet (Orphanet)
- 521